<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>USES OF CIMIRACEMATE A AND RELATED COMPOUNDS FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inventor(s)</strong></td>
<td>LAU, ALLAN SIK YIN; YANG, CINDY LAI HUNG</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2013</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/206718">http://hdl.handle.net/10722/206718</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
USES OF CIMIRACEMATE A AND RELATED COMPOUNDS FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES

Inventors: Allan Sik Yin Lau, Hong Kong (CN); Cindy Lai Hung Yang, Hong Kong (CN)

Assignees: VERSITECH LIMITED, HONG KONG (CN); PURAPHARM COMPANY LIMITED, HONG KONG (CN)

Appl. No.: 13/812,265
PCT Filed: Jul. 29, 2011
PCT No.: PCT/IB11/02582
§ 371 (c)(1), (2), (4) Date: Aug. 23, 2013

Related U.S. Application Data

 Provisional application No. 61/369,428, filed on Jul. 30, 2010.

The present invention pertains to Cimiracemate A and related compounds that are useful as inhibitors of 5-lipoxygenase (5-LOX) activity and various proinflammatory mediators such as lipoxins, leukotrienes (e.g., LTA4, LTE4, LTB4, LTD4, and LTE4), prostaglandins, and thromboxanes. The present invention also provides therapeutic methods and compositions for treatment of inflammation and inflammatory conditions, including allergic reactions, diseases associated with cell proliferation, neoangiogenesis, and cardiovascular diseases.
**FIG. 1A**

**Effect of Cim A on 5-LOX activity**

<table>
<thead>
<tr>
<th>Condition</th>
<th>5-LOX (nmol/min/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank</td>
<td>12</td>
</tr>
<tr>
<td>Enzyme</td>
<td>10</td>
</tr>
<tr>
<td>Enzyme + Cim A 12.5</td>
<td>6</td>
</tr>
<tr>
<td>Enzyme + Cim A 25</td>
<td>4</td>
</tr>
<tr>
<td>Enzyme + Cim A 50</td>
<td>2</td>
</tr>
</tbody>
</table>

* p < 0.05
** p < 0.01

**FIG. 1B**

**Effect of Cim A on LTB4 production**

<table>
<thead>
<tr>
<th>Condition</th>
<th>LTB4 (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td>0</td>
</tr>
<tr>
<td>DMSO + AL318/</td>
<td>45000</td>
</tr>
<tr>
<td>Cim A 25 + AL318/</td>
<td>15000</td>
</tr>
<tr>
<td>Cim A 50 + AL318/</td>
<td>5000</td>
</tr>
</tbody>
</table>

*** p < 0.001
Milled powder of Convolvulus racemosa (1.8 kg dry wt.)

- Suspended in Milli-Q water
- Extracted the supernatant with EtOAc (1:3)

Extract (14.97 g)

Reconstituted and then partitioned subsequently with n-C6H14, EtOAc, and n-BuOH

- n-C6H14 Fraction
- EtOAc Fraction
- n-BuOH Fraction

Subjected to flash-chromatography using silica gel and a step-wise gradient solvent system.

- Fr. 1: n-C6H14 and EtOAc (1:1)
- Fr. 2: EtOAc (100%)
- Fr. 3: EtOAc and CH2OH (4:1)
- Fr. 4: EtOAc and CH2OH (3:2)
- Fr. 5: EtOAc and CH2OH (3:7)
- Fr. 6: CH2OH (100%)

Showed anti-inflammatory activity

Further purified by using reverse phase HPLC

- Fr. 1
- Fr. 2
- Fr. 3
- Fr. 4
- Fr. 5
- Fr. 6

Showed anti-inflammatory activity

Further purified by using reverse phase HPLC

- Fr. 1
- Fr. 2
- Fr. 7

Showed anti-inflammatory activity

FIG. 2
FIG. 7A

Mock  |  Cim A
LPS  -  +  |  -  +

phospho-ERK1/2
Total ERK1/2

FIG. 7B

phospho p38 MAPK
Total p38 MAPK

FIG. 7C

NF-κBp65
Lamin B

Lane: 1  2  3  4

Lane:

Identity

45  40  35  30  25  20  15  10  5  0

*
USES OF CIMIRACEMATE A AND RELATED COMPOUNDS FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES

CROSS-REFERENCE TO A RELATED APPLICATION

[0001] This application claims the benefit of U.S. provisional application Ser. No. 61/369,428, filed Jul. 30, 2010, which is incorporated herein by reference in its entirety, including all figures, tables and sequences.

[0002] The Sequence Listing for this application is labeled “As-filed_ST25.txt”, which was created on Jul. 26, 2011, and is 2 KB. The entire contents are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

[0003] 5-lipoxygenase (5-LOX), expressed primarily in leukocytes including monocytes and macrophages, is the rate-limiting enzyme in the biosynthesis of proinflammatory leukotriene lipid mediators. Leukotrienes have been found to be involved in many inflammatory diseases, allergic reactions, diseases associated with cell proliferation, neangiogenesis, and cardiovascular diseases. The biosynthesis of leukotrienes begins with the conversion of arachidonic acid by 5-LOX to the epoxide known as Leukotriene A, which is subsequently converted to other leukotrienes such as Leukotriene B, Leukotriene C, Leukotriene D, and Leukotriene E. Leukotrienes are of great local and systemic importance in the regulation of inflammatory responses, such as bronchoconstriction, edema, and vasoconstriction.

[0004] Leukotrienes, a group of locally acting hormones that actively recruit eosinophils and stimulate the extravasation of plasma, are potent proinflammatory mediators. Leukotriene B is a potent chemoattractant for macrophages, neutrophils, and eosinophils. Leukotriene B causes adhesion and chemotactic movement of leukocytes and stimulates aggregation, enzyme release, and generation of superoxide in neutrophils. Cysteinyl leukotrienes (cysLTs), such as LT, LT, and LT, cause mucus secretion, cell migration, inflammatory cell infiltration, increased vascular permeability, tissue edema, pulmonary edema, and bronchoconstriction. Leukotrienes also increase chloride secretion in colonic mucosa and cause smooth muscle contractions in a number of tissues including the colon.

[0005] It is well documented that blocking the effects of leukotrienes would be beneficial to an array of diseases. Recently published studies and case reports have demonstrated that anti-leukotriene agents alleviate symptoms commonly associated with asthma, including exercise-induced asthma, rhinitis, chronic obstructive pulmonary disease, interstitial lung disease, chronic urticaria, atopic dermatitis, allergic fungal diseases, nasal polyps, and parasitic lung disease; and non-asthma related diseases, including migraine, respiratory syncytial virus postbronchiolitis, systemic mastocytosis, cystic fibrosis, pancreatitis, vulvovaginal candidiasis, cancer, atherosclerosis, eosinophilic cystitis, otitis media, pupillary constriction, and eosinophilic gastrointestinal disorders.

[0006] Inhibition of leukotrienes is also useful to treat diseases, including allergy and inflammation accompanying allergic diseases of respiratory, gastrointestinal and dermatological systems; tumor and cancer such as urological tumors (e.g. renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer); adipose tissue inflammation; cerebrovascular and cardiovascular diseases such as neuroangiogenesis, myocardial infarction, acute myocardial infarction, stroke, atherosclerosis, thrombosis, coronary angioplasty, aortic aneurysm, vascular inflammation, intimal hyperplasia, hyperlipidemia-dependent aortic aneurysm, cystic fibrosis lung diseases; sleep-disorder breathing; obstructive sleep apnea (OSA); chronic inflammatory bowel diseases; Crohn’s disease; allergic rhinitis; fractured bone; arthritis; and chronic obstructive pulmonary disease (COPD).

[0007] The capacity of leukotrienes to act as potent proinflammatory mediators drives the development of anti-leukotriene agents, which are recognized as high potential therapeutics for a variety of diseases. Anti-leukotrienes are classified into two major categories: leukotriene receptor antagonists and synthesis inhibitors. Although leukotriene receptor antagonist drugs such as montelukast, zafirlukast and pranlukast represent important therapeutic advances, particularly in the treatment of asthma, clinical studies have revealed that these leukotriene receptor antagonists cause side effects such as gastrointestinal disturbances, hypersensitivity reactions, sleep disorders, increased bleeding tendency, vasculitis rash, worsening of pulmonary symptoms, and cardiac complications. Use of montelukast is also reported as associated with higher incidence of Churg-Strauss syndrome and increased risk of neuropsychiatric disturbance, including of insomnia, agitation, aggression, anxiety, dream abnormalities, hallucinations, depression, and suicidal thoughts. Therefore, there is a need for developing alternative anti-leukotriene agents with improved efficacy and safety.

[0008] Traditional Chinese medicine has been practiced by the Chinese people for 2-3 millennia. It deals with pathology, and diagnosis, treatment and prevention of diseases. Chinese medicinal materials have been recorded in various pharmacopoeia. One of the classical references for medicinal herbs is Ben Cao Gang Mu written by Li, Shizhen in the late 14th Century. The book contains about 2,500 items of herbs and other products including animals and minerals.

[0009] Various species of Cimicifuga have been used as therapeutics for inflammatory conditions in Chinese, Korean, and Japanese medicine. C. racemosa (also known as black cohosh) and its counterparts C. heracleifolia, C. foetida and C. dahurica have been used as traditional medicinal herbs to treat fever, pain and inflammation in Asian countries including China, Japan and Korea. C. racemosa species also have a long and diverse history of medicinal use in the United States and Canada. As a result, the toxicity of the herbs as well as their chemical constituents in human uses has been well tested for centuries.

[0010] Cinaminacemate A, an ester formed between isofurferic acid and 3-(3,4-dihydroxylphenyl)-2-keto-propanol, is a naturally-occurring compound that can be isolated from many C. racemosa species, including C. racemosa. The present inventors have identified that Cinaminacemate A suppresses LPS-induced TNF-α in human macrophages and inhibits LPS-induced MAP kinase activities. Cinaminacemate A may have additional health benefits, including acting as reactive oxygen species scavengers. Cinaminacemate A and its related compounds, however, have not previously been reported to play any role in inhibition of 5-lipoxygenase (5-LOX) activity or leukotriene biosynthesis.
BRIEF SUMMARY

[0011] The present invention pertains to novel uses of compounds of Formula I and compositions comprising these compounds as 5-lipoxygenase (5-LOX) inhibitors and anti-leukotriene agents. The compounds have the following structure:

![Formula I]

wherein

[0012] R₁ is alkyl;
[0013] R₂ is H or alkyl;
[0014] R₃, R₄, and R₅ are independently —H, acyl, halo, haloalkyl, amino, alkyamino, hydroxyl, alkyl, hydroxylalkyl, or —COOH;
[0015] R₆ is —O or —NH;
[0016] R₇, —H, alkyl, alkoxy, hydroxylalkyl, hydroxyl, or halo;
[0017] R₈, R₉, and R₁₀ are independently —H, acyl, halo, amino, alkyamino, hydroxyl, alkyl, hydroxylalkyl, or —COOH;
[0018] R₁₁ is H or alkyl; and
[0019] R₁₂ is H or alkyl.

[0020] The present compounds and compositions are useful to treat inflammatory diseases, allergic reactions, diseases associated with cell proliferation, neangiogenesis, and cardiovascular diseases. In certain embodiments, due to the modulation effects of these compounds on 5-lipoxygenase and TNF-α, they have immunomodulatory activity that is not specifically associated with inflammation.

[0021] One embodiment of the present invention pertains to uses of Cimicifugata A. Further embodiment is uses of Cimicifugata A isolated from herbs such as Cimicifuga species. Advantageously, Cimicifugata A potently inhibits 5-lipoxygenase activity and blocks biosynthesis of lipoxins, leukotrienes (e.g., LTA₄, LTB₄, LTC₄, LTD₄, and LTE₄), prostaglandins, and thromboxanes.

[0022] The present invention is also directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound of Formula I. In a preferred embodiment, the composition contains the compound of Formula I as the active ingredient.

[0023] In certain embodiments, the compounds and pharmaceutical compositions of the present invention are useful to treat or ameliorate diseases, such as for example, asthma, exercise-induced asthma, rhinitis, chronic obstructive pulmonary disease, interstitial lung disease, chronic urticaria, atopic dermatitis, allergic fungal diseases, nasal polypsis, parasal sinus disease, migraine, respiratory syncytial virus post-bronchiolitis, systemic mastocytosis, cystic fibrosis, pancreatitis, valvulovaginal candidiasis, cancer, atherosclerosis, eosinophilic cystitis, otitis media, capsular contracture, and eosinophilic gastrointestinal disorders.

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] FIGS. 1A-B show inhibitory effects of Cimicifugata A on 5-lipoxygenase (5-LOX) and production of Leukotriene B₄ (LTB₄).

[0025] FIG. 2 shows an extraction scheme of Cimicifugata A (B22EES1-8-3) from Cimicifuga racemosa. Cimicifuga racemosa (1.8 kg) was milled and extracted with 500 mL milli-Q water for 1 hr with continuous sonication. The collected supernatant was then partitioned with ethyl acetate (EtOAc) (1:1). The resulting dried EtOAc extract was reconstituted and then sequentially partitioned with hexane (n-C₆H₁₄), EtOAc and butanol (n-BuOH). Using bioassay guided fractionation scheme, the fractions showing inhibitory effects on LPS-induced TNF-α production were subjected to silica gel 60A (35-75 μm) chromatography and reversed-phase high-performance liquid chromatography using gradient elution until a single compound with anti-inflammatory activity was obtained.

[0026] FIGS. 3A-3B show HPLC chromatogram and UV absorbance of B22EES1-8-3. The compound was purified by reversed-phase HPLC using gradient elution from 25% to 90% of acetonitrile at a flow rate of 1 mL min⁻¹. (A) A single peak was detected using Photo-diode Array detector at 254, 210 and 280 nm. B22EES1-8-3 was eluted at approximate 9.4 min. (B) The UV absorbance of B22EES1-8-3 maximized at 290 and 325 nm which revealed that it had a conjugated aromatic system.

[0027] FIG. 4 shows the ¹H (upper panel) and ¹³C NMR (lower panel) spectra of B22EES1-8-3. The structure of B22EES1-8-3 was elucidated by a Bruker 500 MHz DRX NMR spectrometer, operating at 500 MHz for ¹H and at 125.765 MHz for ¹³C NMR, using methanol-d as the solvent.

[0028] FIGS. 5A-5B show a bioassay guided fractionation of Cimicifuga racemosa. Primary blood macrophages (PB-Mac) were treated with different C. racemosa fractions at 100 μg/mL for 24 hr prior to the addition of 20 ng/mL LPS for 3 hr. RT-PCR (A) and quantitative RT-PCR (B) assays of TNF-α and GAPDH were performed afterwards. The results shown are representative of at least three independent experiments, with cells obtained from different donors. * P<0.05, compared with the corresponding control.

[0029] FIGS. 6A-6B show inhibition of LPS-induced TNF-α production by B22EES1-8-3 and dexamethasone. PB-Mac were incubated with (A) 140 μM B22EES1-8-3 or (B) 1.3 or 5.1 μM dexamethasone (Dex) for 24 hr prior to the addition of 1 ng/mL and 10 ng/mL LPS for another 24 hr. The culture supernatants were collected and assayed for TNF-α by ELISA. The results shown were the mean values ± standard deviation (S.D.) of 6 independent experiments, with cells obtained from different donors. * P<0.05, compared with the corresponding control.

[0030] FIGS. 7A-7C show the effects of Cim A (B22EES1-8-3) on LPS-induced phosphorylation (phospho-) of ERK1/2 and p38 MAP kinases, and nuclear translocation of NF-κB p65. PB-Mac were incubated with B22EES1-8-3 (140μM) for 24 hr prior to the addition of 10 ng/mL LPS for an additional 15 min. Cytoplasmic (A, B) and nuclear (C) proteins were harvested for Western Blotting: (A) Cytoplasmic proteins: phospho-ERK1/2 and total ERK1/2. (B) Cytoplasmic proteins: phospho-p38 and total p38 kinase. (C) Nuclear proteins: upper panel, NF-κB p65 and lamin B; lower panel, the intensity of corresponding lanes in the gel photograph of NF-κB p65 was shown. The results shown are representative
of at least three independent experiments, with cells obtained from different donors. * P<0.05, compared with the corresponding control.

[0031] FIGS. 8A-8B show the HPLC chromatograms of CF22EES1-8 (A) and CH22EES1-8 (B). Herbs C. foetida and C. heracleifolia were extracted following the extraction procedure of C. racemosus. Their extracts (CF22EES1-8 and CH22EES1-8) were injected into the HPLC using the same condition as that of B22EES1-8-3 and the chromatograms were recorded. The chromatograms showed the presence of a compound (with *) with retention time at approximate 9.4 minutes.

[0032] FIGS. 9A-9C show the UPLC chromatograms and HRESI-MS spectra of (A) B22EES1-8-3, (B) CF22EES1-8, and (C) CH22EES1-8. Herbs C. foetida and C. heracleifolia were extracted following the extraction procedure of C. racemosus. Their fractions (CF22EES1-8 and CH22EES1-8) were injected into a UPLC-coupled high-resolution ESI-TOF-MS using the same condition as that of B22EES1-8-3. The chromatograms showed the presence of a compound (with *) with retention time at approximately 6 min and with an ion peak at 357 m/z.

BRIEF DESCRIPTION OF THE SEQUENCES

[0033] SEQ ID NO:1 is a primer useful according to the present invention.

[0034] SEQ ID NO:2 is a primer useful according to the present invention.

[0035] SEQ ID NO:3 is a primer useful according to the present invention.

[0036] SEQ ID NO:4 is a primer useful according to the present invention.

DETAILED DESCRIPTION

[0037] The present invention pertains to novel uses, as 5-lipoxygenase (5-LOX) inhibitors and anti-leukotriene agents, of compounds of Formula 1 and compositions comprising these compounds. The compounds and compositions of the present invention are useful to treat or ameliorate inflammatory diseases, allergic reactions, diseases associated with cell proliferation, neoangiogenesis, and cardiovascular diseases. Specifically exemplified herein is the therapeutic use of Cimicifugae A (Cim A).

Compounds

[0038] The present invention provides therapeutic compounds of Formula 1, which are potent 5-lipoxygenase (5-LOX) inhibitors and anti-leukotriene agents. The compounds have the following structure:

![Formula 1](image)

Wherein

[0039] R₆ is alkyl;

[0040] R₇ is H or alkyl;

[0041] R₈, R₉, and R₁₀ are independently —H, acyl, halo, haloalkyl, amino, alkylamino, hydroxyl, alkyl, hydroxyalkyl, or —COOH;

[0042] R₁₁ is —O or —NH₂;

[0043] R₁₂ is —H, alkyl, alkoxy, hydroxyalkyl, hydroxyl, or halo;

[0044] R₁₃, R₁₄, and R₁₅ are independently —H, acyl, halo, amino, alkylamino, hydroxyl, alkyl, hydroxyalkyl, or —COOH;

[0045] R₁₆ is H or alkyl; and

[0046] R₁₇ is H or alkyl.

“Alkyl” means linear saturated monovalent radicals of one to eight carbon atoms or a branched saturated monovalent of three to eight carbon atoms. It may include hydrocarbon radicals of one to four or one to three carbon atoms, which may be linear. Examples include methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and the like.

“Acy1” means a radical —(O)R where R is hydrogen, alkyl or cycloalkyl, or heterocycloalkyl. Examples include formyl, acetyl, ethylcarbonyl, and the like.

“Halo” means fluoro, chloro, bromo, or iodo, such as bromo and chloro.

“Haloalkyl” means alkyl substituted with one or more same or different halo atoms, e.g. —CH₃Cl, —CH₂Br, —CF₃, —CH₂CH₂Cl, —CH₂CCl₃, and the like.

An “amino” is intended to mean the radical —NH₂.

“Alkylamino” means a radical —NR wherein R, R₁, and R₁₂ each independently is an alkyl group. Examples include methylamino, (1-methylethyl)amino, dimethylamino, methylethylamino, di(1-methylethyl)amino, and the like.

A “hydroxy” is intended to mean the radical —OH.

“Hydroxyalkyl” means an alkyl radical as defined herein, substituted with one or more, preferably one, two or three hydroxy groups. Representative examples include, but are not limited to, 2-hydroxyethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-1-(hydroxymethyl), 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxy-propyl, preferably 2-hydroxyethyl, preferably 2,3-dihydroxypropyl and 1-(hydroxymethyl)2-hydroxyethyl.

An “alkoxy” is intended to mean the radical —OR, wherein R is an alkyl group. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, and the like.

[0047] The present invention further pertains to isolated enantiomeric compounds. The isolated enantiomeric forms of the compounds of the invention are substantially free from one another (i.e., in enantiomeric excess). In other words, the “R” forms of the compounds are substantially free from the “S” forms of the compounds and are, thus, in enantiomeric excess of the “S” forms. Conversely, “S” forms of the compounds are substantially free of “R” forms of the compounds and are, thus, in enantiomeric excess of the “R” forms. In one embodiment of the invention, the isolated enantiomeric compounds are in at least about 80% enantiomeric excess. In a preferred embodiment, the compounds are in at least about 90% enantiomeric excess. In a more preferred embodiment, the compounds are in at least about 95% enantiomeric excess. In an even more preferred embodiment, the compounds are in at least about 97.5% enantiomeric excess.
embodiments, the compounds are at least about 99% enantiomeric excess. In this context, the applicants incorporate herein by reference, in its entirety, International Application No.: PCT/IB2009/055970.

[0048] In an embodiment, the present invention pertains to uses of isolated compounds. The compounds of Formula I can be isolated from a medicinal plant such as Cinchifera species, including Cinchifera racemosa, Cinchifera heraclefolia, and Cinchifera foetida.

[0049] As used herein, “isolated” refers to compounds that have been removed from any environment in which they may exist in nature. For example, isolated Cin A would not refer to the Cin A compound as it exists in Cinchifera species such as C. racemosa. In preferred embodiments, the compounds of the present invention are at least 75% pure, preferably at least 90% pure, more preferably are more than 95% pure, and most preferably are more than 99% pure (substantially pure).

[0050] In one embodiment, the present invention pertains to therapeutic uses of compounds of Formula I, wherein R1 is H, R2 is H, and R3 is H. In another embodiment, the present invention pertains to therapeutic uses of the compounds of Formula I, wherein R1 is a methyl group.

[0051] In a specific embodiment, the present invention pertains to therapeutic uses of Cinnaevate A (Cin A), having the following structure:

[0052] Surprisingly, it has now been discovered that Cin A and its related compounds potently inhibit 5-LOX activity and block the biosynthesis of leukotrienes such as LTD5. It has been reported that 5-LOX inhibition blocks biosynthesis and activity of a wide range of proinflammatory mediators, including lipoxins, leukotrienes, prostaglandins, and thromboxanes. Particularly, it is well documented that inhibition of 5-LOX blocks biosynthesis of leukotrienes. Therefore, the present compounds are useful for preventing, reversing or alleviating pathological conditions induced by leukotrienes.

[0053] In addition, Cin A and its related compounds can inhibit aldose reductase, cyclooxygenase, HIV integrase, adrenergic (beta1), and phospholipase A2 activity. Cin A can also be used to reduce levels of cAMP and CGMP.

[0054] In addition, the present inventors have discovered that Cin A inhibits TNF-alpha induction and abrogates MAP kinase and NF-KB activation. TNF-alpha (TNF-α), MAP kinase and NF-KB are mediators that play a key role in production of cytokine and regulation of a range of immune responses. Therefore, Cin A can also be used to regulate the downstream effectors of TNF-alpha.

[0055] The present inventors have also discovered that the effects of Cin A on the regulation of cytokines occur via its activity in the modulation of signaling kinase and transcription factor activities. Cin A suppresses mitogen induced inflammatory response, which makes this molecule useful for treatment of a variety of clinical conditions. Since overproduction of TNF-alpha is toxic and can result in severe complications, limiting the overwhelming inflammatory response can be beneficial to patients in clinical management.

[0056] Cin A can be isolated from Cinchifera species, such as Cinchifera racemosa, Cinchifera heraclefolia, and Cinchifera foetida using unique isolation and bioassay-guided procedures developed by the present inventors (Examples 3-4).

Treatment of Inflammatory Diseases and/or Immune Disorders

[0057] The present invention provides methods for treatment or amelioration of inflammatory diseases and/or immune disorders, particularly diseases or disorders associated with 5-lipoxygenase activity and/or leukotriene overproduction. In one embodiment, the present invention provides methods for treatment or amelioration of inflammatory diseases and/or immune disorders that are not disclosed as diseases that are to be treated in accordance with the teachings in International Application No.: PCT/IB2009/055970.

[0058] In certain embodiments, the compounds and compositions of the present invention are useful to treat or ameliorate conditions, including but not limited to, inflammation, allergic reactions, diseases associated with cell proliferation, neangiogenesis, and cardiovascular diseases. The method comprizes administering, to a subject in need of such treatment, an effective amount of the compounds and compositions of the present invention.

[0059] The compounds and compositions of the present invention are particularly useful to treat or ameliorate diseases in which inhibition of synthesis and activity of lipoxins, leukotrienes (e.g., LTA4, LTB4, LTC4, LTD4, LTE4) and prostaglandins, and thromboxanes would be beneficial.

[0060] The term “-effective amount,” as used herein, refers to an amount that is capable of treating or ameliorating a disease or condition or otherwise capable of producing an intended therapeutic effect. In certain embodiments, the effective amount enables a 5%, 10%, 20%, 30%, 50%, 60%, 70%, 80%, 90%, 95%, 99% and 100% reduction in 5-LOX activity. Additionally, or alternatively, the effective amount enables a 5%, 10%, 20%, 30%, 50%, 60%, 70%, 80%, 90%, 95%, 99% and 100% reduction in the levels and/or biosynthesis of lipoxins, leukotrienes (e.g., LTA4, LTB4, LTC4, LTD4, LTE4) and prostaglandins, and/or thromboxanes.

[0061] The term “subject,” as used herein, describes an organism, including mammals such as primates, to which treatment with the compositions according to the present invention can be provided. Mammalian species that can benefit from the disclosed methods of treatment include, but are not limited to, apes, chimpanzees, orangutans, humans, monkeys; and domesticated animals such as dogs, cats, horses, cattle, pigs, sheep, goats, chickens, mice, rats, guinea pigs, and hamsters.

[0062] The compounds and pharmaceutical compositions of the present invention can be used in the treatment or amelioration of inflammatory symptoms in any disease, condition or disorder where immune and/or inflammation suppression is beneficial. Inflammatory diseases, conditions or disorders in which the compounds and compositions of the present invention can be used to inhibit unwanted immune reactions and inflammation include, but are not limited to, arthritis, including but not limited to, rheumatoid arthritis, and other diseases, conditions or disorders of the joints or musculoskeletal system in which immune and/or inflammation suppression is beneficial.
The compounds and pharmaceutical compositions of the present invention are useful to treat or ameliorate asthma and asthma-associated diseases, such as exercise-induced asthma, rhinitis, chronic obstructive pulmonary disease, interstitial lung disease, chronic urticaria, atopic dermatitis, allergic fungal diseases, nasal polyposis, and paranasal sinus disease.

In addition, the compounds and pharmaceutical compositions of the present invention are useful to treat or ameliorate non-asthma-related diseases, including migraine, respiratory syncytial virus postbronchiolitis, systemic mastocytosis, cystic fibrosis, pancreatitis, vulvovaginal candidiasis, cancer, atherosclerosis, eosinophilia, cystitis, otitis media, capsular contracture, and eosinophilic gastroenteritis disorders.

In addition, the compounds and pharmaceutical compositions of the present invention are useful to treat or ameliorate diseases, including allergy and inflammation accompanying allergic diseases of respiratory, gastrointestinal, and dermatological systems; adipose tissue inflammation; chronic inflammatory bowel diseases; Crohn’s disease; allergic rhinitis; fractured bone; arthritis; and tumor and cancer such as urological tumors (e.g., renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer), neurofibromatosis, and pancreatic cancer.

The compounds and pharmaceutical compositions of the present invention are useful to treat or ameliorate diseases, including cerebrovascular and cardiovascular diseases such as myocardial infarction, acute myocardial infarction, stroke, diabetes, atherosclerosis, thrombosis, coronary angioplasty, aortic aneurysm, vascular inflammation, intimal hyperplasia, hyperlipidemia-dependent aortic aneurysm; cystic fibrosis lung diseases; sleep-disorder breathing, obstructive sleep apnea (OSA); and chronic obstructive pulmonary disease (COPD).

The compounds and pharmaceutical compositions of the present invention are useful to treat or ameliorate diseases, including pulmonary disorders including diseases such as asthma, chronic bronchitis, and related obstructive airway diseases; allergies and allergic reactions such as allergic rhinitis, contact dermatitis, allergic conjunctivitis, and the like; inflammation such as arthritis or inflammatory bowel disease; pain; skin disorders such as psoriasis, atopic eczema, and the like; cardiovascular disorders such as angina, myocardial ischemia, hypertension, platelet aggregation and the like; renal insufficiency arising from ischemia induced by immunological or chemical (cyclosporin) etiology; migraine or cluster headache; ocular conditions such as uveitis; hepatitis resulting from chemical, immunological or infectious stimuli; trauma or shock states such as burn injuries, endotoxemia and the like; allograft rejection; chronic lung diseases such as cystic fibrosis, bronchitis and other small and large-airway diseases; and cholecystitis.

Moreover, the compounds and compositions are also useful to treat or ameliorate inflammation associated with atherosclerosis; arteriosclerosis; atherosclerotic heart disease; reperfusion injury; cardiac arrest; myocardial infarction; vascular inflammatory disorders including cerebrovascular disease (stroke); respiratory distress syndrome and other cardiopulmonary diseases, conditions or disorders where immune and/or inflammation suppression would be beneficial.

In addition, the compounds and compositions are also useful to treat or ameliorate inflammation associated with peptic ulcer; ulcerative colitis, Crohn’s Disease, irritable bowel syndrome, other inflammatory bowel conditions, and other diseases, conditions or disorders of the gastrointestinal tract where immune inflammation suppression would be beneficial; hepatic fibrosis; liver cirrhosis and other hepatic diseases, conditions or disorders where immune and/or inflammation suppression would be beneficial; thyroiditis and other glandular diseases, conditions or disorders where immune and/or inflammation suppression would be beneficial; glomerulonephritis and other renal and urologic diseases, conditions or disorders where immune and/or inflammation suppression would be beneficial.

In addition, the compounds and compositions are also useful to treat or ameliorate inflammation associated with post-traumatic inflammation; septic shock; infectious diseases where immune and/or inflammation suppression would be beneficial; inflammatory complications and side effects of surgery where immune and/or inflammation suppression would be beneficial; bone marrow transplantation and other transplantation complications and side effects where immune and/or inflammation suppression would be beneficial; inflammatory and/or immune complications and side effects of gene therapy, e.g., due to infection with a viral carrier; and inflammation associated with acquired immune deficiency syndrome (AIDS).

Further, the compounds and compositions are also useful to inhibit macrophage or T cell associated aspects of an immune response that are not associated with inflammation. The compounds and compositions are able to inhibit macrophage or T cell activities including, but not limited to, macrophage antigen-presenting activity, macrophage cytokine production, T cell cytokine production, T cell adhesion activity, T cell proliferation, etc. Thus, the peptides, peptide derivatives and compositions are useful to suppress or inhibit a humoral and/or cellular immune response.

The compounds and compositions are also useful to treat or ameliorate monocyte and leukocyte proliferative diseases, e.g., leukemia, by reducing the amount of monocytes and lymphocytes.

The compounds and pharmaceutical compositions of the invention are further useful for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial tissues, organs and tissues, such as corneas, bone marrow, organs, lenses, pacemakers, natural and artificial skin tissue, and the like.

The compounds and compositions are also useful to treat or ameliorate inflammation associated with hypersensitivity; allergic reactions; asthma; systemic lupus erythematosus; collagen diseases and other autoimmune diseases, conditions or disorders in which immune and/or inflammation suppression is beneficial.

The compounds and compositions are also useful to treat or ameliorate inflammation associated with otitis and other otolaryngological diseases, conditions or disorders where immune and/or inflammation suppression would be beneficial; dermatitis and other dermal diseases, conditions or disorders where immune and/or inflammation suppression would be beneficial; periodontal diseases and other dental diseases, conditions or disorders where immune and/or inflammation suppression would be beneficial.

In addition, the compounds and compositions are also useful to treat or ameliorate inflammation associated with posterior uveitis; intermediate uveitis; anterior uveitis; conjunctivitis; choriorretinitis; uveoretinitis; optic neuritis; intracocular inflammation, such as retinitis and cystoid macu-
lar edema; sympathetic ophthalmia; scleritis; retinitis pigmentosa; immune and inflammatory components of degenerative foncus disease; inflammatory components of ocular trauma; ocular inflammation caused by infection; proliferative vitreoretinopathies; acute ischemic optic neuropathy; excessive scarring, for example, following glaucoma filtration operation; immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, conditions or disorders where immune and/or inflammation suppression would be beneficial.

Moreover, the compounds and compositions are also useful to treat or ameliorate inflammation associated with autoimmune diseases and conditions or disorders where, both in the central nervous system (CNS) and in any other organ, immune and/or inflammation suppression would be beneficial; Parkinson’s disease; complications and/or side effects from treatment of Parkinson’s disease; AIDS-related dementia complex (HIV-related encephalopathy); Devic’s disease; Sydenham chorea; Alzheimer’s disease and other degenerative diseases, conditions or disorders of the central nervous system where immune and/or inflammation suppression would be beneficial; inflammatory components of strokes; post-polio syndrome; immune and inflammatory components of psychiatric disorders; myelitis; encephalitis; subacute sclerosing panencephalitis; encephalomyelitis; acute neuropathy; subacute neuropathy; chronic neuropathy; Guillain-Barre syndrome; Sydenham chorea; myasthenia gravis; pseudotumor cerebri; Down’s Syndrome; Huntington’s disease; amyotrophic lateral sclerosis; inflammatory components of central nervous system (CNS) compression or CNS trauma or cerebrovascular accidents (stroke) or infections or hypoxia-ischemia of the CNS; inflammatory components of muscular atrophies and dystrophies; and immune and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems where immune and/or inflammation suppression would be beneficial.

In yet another embodiment, the compounds and compositions of the invention are useful to restore immune privilege at an immune privileged site which has lost its immune privilege such as brain, eye and testis.

In a further embodiment, the present method comprises: determining the level of one or more biomarker (such as 5-LOX, leukotrienes (e.g., LTA₄, LTB₄, LTC₄, LTD₄, and LTE₄), prostaglandins, lipoxins, thromboxane, TNF-α, IFN, NF-KB, cAMP, CGMP, and MAP kinase) in a subject, and prescribing the compounds and compositions of the invention if reduction of the level of said one or more biomarkers would produce beneficial therapeutic effects.

**Therapeutic Compositions and Formulations**

The present invention also provides for therapeutic or pharmaceutical compositions comprising a compound of the invention in a form that can be combined with a pharmaceutically acceptable carrier. In this context, the composition may be, for example, isolated or substantially pure. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum oil such as mineral oil, vegetable oil such as peanut oil, soybean oil, and sesame oil, animal oil, or oil of synthetic origin. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Particularly preferred pharmaceutical carriers for treatment of or amelioration of inflammation in the central nervous system are carriers that can penetrate the blood/brain barrier. As used herein carriers do not include the natural plant material as it exists in nature.

The present invention also pertains to uses of prodrugs and metabolites of the compounds. The term “prodrug,” as used herein, refers to a metabolic precursor of a compound of the present invention or pharmaceutically acceptable form thereof. In general, a prodrug comprises a functional derivative of a compound, which may be inactive when administered to a subject, but is readily convertible in vivo into an active metabolite compound. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985. Preferably, a prodrug of the present invention enhances desirable qualities of the compound of the present invention including, but not limited to, solubility, bioavailability, and stability. Hence, the compounds employed in the present methods may, if desired, be delivered in a prodrug form. Prodrugs of the compounds employed in the present invention may be prepared by modifying functional groups present in the compound such that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.

The term “metabolite,” refers to a pharmacologically active product, including for example, an active intermediate or an ultimate product, produced through in vivo metabolism of a compound of the present invention in a subject. A metabolite may result, for example, from the anabolic and/or catabolic processes of the administered compound in a subject, including but not limited to, the oxidation, reduction, hydrolysis, amidation, deamination, esterification, deesterification, enzymatic cleavage, and the like.

Metabolites are typically identified by preparing a radiolabelled (e.g., ¹⁴C or ³²H) isotope of a compound of the present invention, administering it parenterally in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to a human, allowing sufficient time for metabolism to occur (typically about 30 seconds to about 30 hours), and isolating its conversion products from the urine, blood or other biological samples. These products are easily isolated since they are labeled (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The structure of metabolites can be determined in conventional fashion, e.g., by MS, LC/MS or NMR analysis. In general, analysis of metabolites is performed according to techniques well known to those skilled in the art of drug metabolism studies.

Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycercyl, propylene, glycol, water, ethanol and the like. The therapeutic composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, capsules, powders, sustained-release formulations and the like. The composition can be formulated with traditional binders and carriers such as triglycerides. Examples of suitable pharmaceutical carriers are described in “Remington’s Pharmaceutical Sciences” by E. W. Martin. Such compositions contain a therapeutically effective amount of the therapeutic composition, together with a suitable amount of
carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In one embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for local injection administration to human beings. Typically, compositions for local injection administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry hypolozialized powder or water free concentrate in a hermetically sealed container such as an ampule or vial containing the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The therapeutic or pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The present invention also provides for the modification of the compound such that it is more stable once administered to a subject, i.e., once administered it has a longer time period of effectiveness as compared to the unmodified compound. Such modifications are well known to those of skill in the art, e.g., microencapsulation, etc. The amount of the therapeutic or pharmaceutical composition of the invention which is effective in the treatment of a particular disease, condition or disorder will depend on the nature of the disease, condition or disorder and can be determined by standard clinical techniques. In general, the dosage ranges from about 0.001 mg/kg to about 500 mg/kg. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease, condition or disorder, and should be decided according to the judgment of the practitioner and each patient’s circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. For example, in order to obtain an effective mg/kg dose for humans based on data generated from rat studies, the effective mg/kg dosage in rats is divided by six.

For instance, suitable unit dosages may be between about 0.01 to about 500 mg, about 0.01 to about 300 mg, about 0.01 to about 200 mg, about 0.01 to about 100 mg, about 0.01 to about 50 mg, about 0.01 to about 30 mg, about 0.01 to about 20 mg, about 0.01 to about 10 mg, about 0.01 to about 5 mg, about 0.01 to about 3 mg, about 0.01 to about 1 mg, or about 0.01 to about 0.5 mg. Such a unit dose may be administered more than once a day, e.g., two or three times a day.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients, e.g., compound, carrier, of the pharmaceutical compositions of the invention.

The compounds of the present invention can also be formulated consistent with traditional Chinese medicine practices. The composition and dosage of the formulation that are effective in the treatment of a particular disease, condition or disorder will depend on the nature of the disease, condition or disorder by standard clinical techniques.

The traditional Chinese medicine in prescription amounts can be readily made into any form of drug, suitable for administering to humans or animals. Suitable forms include, for example, tinctures, decoctions, and dry extracts. These can be taken orally, applied through venous injection or mucous membranes. The active ingredient can also be formulated into capsules, granules, powder, pellets, pastilles, suppositories, oral solutions, pasteurized gastroenteric suspension injections, small or large amounts of injection, frozen powder injections, pasteurized powder injections and the like. All of the above-mentioned methods are known to people skilled in the art, described in books and commonly used by practitioners of herbal medicine.

In preferred embodiments, the compounds of the present invention are prepared as discrete units such as granules (e.g., wet granules, dry granules); capsules, cachets or tablets, each containing a predetermined amount of the active ingredient.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary, depending on the type of the condition and the subject to be treated. In general, a therapeutic composition contains from about 5% to about 95% active ingredient (w/w). More specifically, a therapeutic composition contains from about 20% (w/w) to about 80%, or about 30% to about 70% active ingredient (w/w).

A tincture is prepared by suspending herbs in a solution of alcohol, such as, for example, wine or liquor. After a period of suspension, the liquid (the alcohol solution) may be administered for example, two or three times a day, one teaspoon each time.

A decoction is a common form of herbal preparation. It is traditionally prepared in a clay pot, but can also be prepared in glass, enamel or stainless steel containers. The formulation can be soaked for a period of time in water and then brought to a boil and simmered until the amount of water is reduced by, for example, half.

An extract is a concentrated preparation of the essential constituents of a medicinal herb. Typically, the essential constituents are extracted from the herbs by suspending the herbs in an appropriate choice of solvent, typically, water, ethanol/water mixture, methanol, butanol, isobutanol, acetone, hexane, petroleum ether or other organic solvents. The extracting process may be further facilitated by means of maceration, percolation, repercolation, counter-current extraction, turbo-extraction, or by carbon dioxide hypercritical (temperature + pressure) extraction. After filtration to rid of herb debris, the extracting solution may be further evaporated and then concentrated to yield a soft extract (extractum spissum) and/or eventually a dried extract, extractum siccum, by means of spray drying, vacuum oven drying, fluid-bed drying or freeze-drying. The soft extract or dried extract may be further dissolved in a suitable liquid to a desired concentration for administering or processed into a form such as pills, capsules, injections, etc.
Materials and Methods

Plant Material

[Cicimifuga racemosa] was purchased from the Glenbrook Farms Herbs and Such, Campbellsville, Ky. Cicimifuga heracleifolia, Cicimifuga foetida and Cicimifuga dahurica were purchased in herbal markets and subsequently authenticated by Purapharm with respect to their identification.

Extraction and Isolation of the Bioactive Molecules

The procedures for plant extraction are shown in FIG. 2. Briefly, Cicimifuga racemosa (1.8 kg) was milled, homogenized and then suspended in (1:5) milli-Q water for 1 hr with continuous sonication. The supernatant was filtered through an analytical filter paper and then partitioned three times with ethyl acetate (EtOAc) (1:1). The resulting EtOAc extract was concentrated to dryness in vacuo at 35°C to yield 14.97 g of a dark brown residue. The residue was reconstituted in methanol (MeOH) and then fractionated by partitioning with hexane (n-C6H14). The MeOH fraction was concentrated and reconstituted in H2O and then partitioned sequentially with EtOAc and butanol (n-BuOH). Four fractions, namely n-C6H14, BuOH, n-BuOH, and H2O were obtained.

The fraction that showed inhibitory effects on LPS-induced TNF-α production was subjected to additional silica gel 60A (35-75 μm) chromatography using n-C6H14, EtOAc, and MeOH to yield six fractions. The active fractions were further purified by reversed-phase high-performance liquid chromatography (HPLC) (Lichrospher 100 RP C18 EC 5μ, 250 x 4.6 mm ID) using a gradient elution from 25% acetonitrile (CH3CN) to 90% CH3CN at a flow rate of 1 mL/min. The best compounds were detected using a microTOF II ES-TOF mass spectrometer (Bruker Daltonics). Data sets were acquired in negative electrospray (ESI) mode in a scan ranging from 100 to 1600 m/z at a sampling rate of 2 Hz. ESI parameters were as follows: capillary, 3.2 kV; nebulizer pressure, 4 bar; dry gas flow, 8 L/min; and dry gas temperature, 200°C.

Chemicals

[Endotoxin (lipopolysaccharide, LPS) from E. coli was purchased from Sigma and used as an inducer of TNF-α expression. Dexamethasone (Sigma) was used as a control drug to inhibit the LPS induction of TNF-α. Cell Culture and Primary Blood Macrophage Isolation Human peripheral blood mononuclear cells (PBMC) were isolated from the buffy coat of healthy donor blood supplied by Hong Kong Red Cross by Ficoll-Paque (Amersham Pharmacia Biotech, Piscataway, N.J.) density gradient centrifugation as described in our previous report[16-18]. In brief, the buffy coat was spun at 3000 rotations per min (rpm) for 15 min to separate the blood cells and the plasma. The heat inactivated serum was filtered for future use.

The cell layer was diluted with phosphate buffered saline (PBS) in a ratio of 1:1. The diluted cells were overlaid on Ficoll-Paque slowly and centrifuged at 2300 rpm for 20 min for separation of mononuclear cells from erythrocytes. The mononuclear cell layer was removed and washed with RPMI 1640 medium until the supernatant was clear.

The cells were finally resuspended in RPMI 1640 medium supplemented with 5% antologous serum and cultured for 1 hr. The non-adherent cells were removed afterwards and the remaining adherent cells were further incubated for another 24 hr at 37°C in 5% carbon dioxide (CO2).

The adherent monocytic cells were detached and seeded onto tissue culture plates and incubated for another 7-14 days in order to differentiate the primary blood monocytic cells to primary blood macrophages (PBMC).

Isolation of DNA and Reverse Transcription

Total RNA from primary blood macrophages with or without treatment of Cicimifuga racemosa fractions was
extracted by TRIzol (Invitrogen). Reverse transcription (RT) of messenger RNA (mRNA) to complementary DNA (cDNA) was done by using the SuperScript II system (Invitrogen) as per the manufacturer’s instruction.

Polymerase Chain Reaction (PCR) and Real-Time RT-PCR

[0111] Semi-quantitative PCR assays of targeted genes were performed in a 25 μl reaction mixture containing 1.5 mM MgCl₂, 0.2 mM of each deoxyribonucleoside triphosphate, 0.25 μM of each primer, 2 units of Taq polymerase (American Pharmacia Biotech, Piscataway, N.J.), and 1 μl of cDNA. PCR primer sets for TNF-α and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were as follows. TNF-α (upstream: 5’-GGCTCCAGCGGTGCT TGTC-3’ (SEQ ID NO: 1); downstream: 5’-AGACCGGATGCGTCGATG-3’ (SEQ ID NO: 2)), and GAPDH (upstream: 5’-ACACAGTCAAGCCATAC-3’ (SEQ ID NO: 3); downstream: 5’-TCCACACCCGTGTGCTGTA-3’ (SEQ ID NO: 4)]. The thermal cycling condition for GAPDH was 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min. The cycling reactions were repeated for 24 more cycles.

Quantitative RT-PCR was performed according to the manufacturer’s instructions by using Applied Biosystems TaqMan® Universal Master Mix. The TNF-α TaqMan® probes were purchased from the Applied Biosystems, and 18s RNA was used as an internal control. Samples were allowed to run in triplicates in each Quantitative RT-PCR assay.

Enzyme-Linked ImmunoSorbent Assay (ELISA)

[0113] Culture supernatants of the LPS-treated PBMac, with or without B222EES1-8-3 pretreatment, were collected at different time intervals and stored at -70°C. The levels of the secreted TNF-α were measured by ELISA kits specific for the cytokine (R&D system, Minneapolis, Minn.).

Preparation of Cellular Extracts

[0114] For the collection of whole cell lysate, PBMac were washed with cold PBS and incubated in cold lysis buffer (50 mM tris(hydroxymethyl)aminomethane-chloride (Tris-Cl) [pH7.4]; 150 mM sodium chloride (NaCl); 50 mM sodium fluoride (NaF); 10 mM β-glycerophosphate; 0.1 mM ethylenediaminetetraacetic acid (EDTA); 10% glycerol; 1% Triton X-100; 1 mM phenylmethylsulfonyl fluoride (PMSF); 1 mM sodium orthovanadate; 2 μg/ml pepstatin A; 2 μg/ml aprotinin and 2 μg/ml leupeptin) for 20 min. The lysate was then centrifuged at 4°C for 15 min. The supernatant was collected and stored at -70°C until use.

[0115] To collect nuclear protein extracts, the treated cells were washed with PBS and resuspended in buffer A (10 mM 4-(2-hydroxyethyl)-1-piperazinencethanesulfonic acid (HEPES) [pH7.9]; 10 mM potassium chloride (KCl); 0.1 mM EDTA, 0.1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM dithiorthreitol (DTT), 0.5 mM phenylmethanesulfonyl fluoride (PMSF), 2 μg aprotinin, 1 mM sodium orthovanadate, 2 μg/ml pepstatin A, 2 μg/ml leupeptin and 50 mM NaF) for 15 min. After that, NP-40 at a final concentration of 0.625% was added and mixed vigorously for cell lysis.

[0116] The cell lysate was centrifuged and the supernatant containing cytoplasmic proteins was collected for storage at -70°C. The nuclear pellet was resuspended in buffer C (20 mM HEPES [pH 7.9], 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and 1 mM PMSF) for 15 min on ice to complete lysis of the nuclear membrane. The nuclear lysate was then centrifuged, and the supernatant containing the nuclear protein was collected and stored at -70°C.

Western Blot Analysis

Whole cell lysate (20 μg) or nuclear protein (2 μg) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes for probing overnight with the respective antibodies specific for the phosphorylated or total form of ERK1/2 and p38 MAPK (Cell Signaling Technology, Beverly, Mass.). NF-κB p65 protein and lamin B (Santa Cruz Biotechnology, Santa Cruz, Calif.). The membranes were incubated with the corresponding secondary antibodies conjugated with horseradish peroxidase (BD Transduction Lab, San Diego, Calif.). The signal was visualized by using enhanced chemiluminescence kit (Amerham Pharmacia Biotech). In order to quantify the results from the Western blots, the gels were scanned and the intensity of the bands was analyzed by a computer program Quantity One from BioRad.

5-LOX Inhibitor Screening Assay

The 5-LOX inhibition assay was performed using Cayman’s Lipoxigenase Inhibitor Screening Assay Kit (Cayman Chemical Company, Ann Arbor, Mich.) according to the manufacturer’s instructions. The 5-LOX enzyme and Linoleic acid (Substrate) were added together in the presence of DMSO (Control) and Cin A at a concentration ranging from 12.5 to 50 μg/ml. After incubation for 5 min, developing agents were added. The production of hydroperoxides was measured and quantified with the use of a microplate reader at wavelength of 490 nm. The 5-LOX enzymatic activity is calculated as nmol/min/ml.

Leukotriene B₄ Production in Activated Human Blood Mononuclear Cells

Freshly isolated human blood mononuclear cells (PBMC) (1x10⁶) were pre-treated with 0.05% DMSO or Cin A (25 or 50 μg/ml) for 1 h, followed by addition of 5 μM Calcium ionophore A23187 (Sigma Aldrich, St. Louis, Mo.) for 30 min. After centrifugation for 1 min, the supernatants were collected. The level of leukotriene B₄ (LTB₄) was measured using LTB₄ parameter assay kit (R&D Systems, Minneapolis, Minn.).

The scope of the invention is not limited by the specific examples and suggested procedures and uses related herein since modifications can be made within such scope from the information provided by this specification to those skilled in the art.

A more complete understanding of the invention can be obtained by reference to the following specific examples of compounds, compositions, and methods of the invention. The following examples illustrate procedures for practicing the invention. These examples should not be construed as limiting. It will be apparent to those skilled in the art that the examples involve use of materials and reagents that are commercially available from known sources, e.g., chemical supply houses, so no details are given regarding them.

Example 1
Prediction of Cimicifugae A as a Lipoxigenase Inhibitor

The Similarity ensemble approach (SEA), a search tool provided by the Shoichet Laboratory in the Department
of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF), quantitatively groups and relates target protein pharmacology based on the set-wise chemical similarity among their ligands\textsuperscript{1,10}. The similarity score between ligand sets is expressed as expectation value (E-value), which can be used to complement scores of chemical similarity generated by BLAST\textsuperscript{11,12}. [0123] SEA search was performed using Cim A as the query compound, and E-values between Cim A and ligands of the target proteins were generated. The Tanimoto coefficient (Tc) of chemical similarity was also calculated. E-value <1x10\textsuperscript{-10} indicates significant similarity, whereas E-value >1.0 indicates insignificant similarity. Tc between 0 to 0.5 indicates insubstantial similarity, whereas Tc>0.5 indicates substantial similarity. [0124] The SEA results suggest that Cim A has inhibitory effects against glucuronidase (beta), lipoxigenase (LOX), aldose reductase, cylooxygenase, HIV integrase, adrenergic (beta1), and phospholipase A2. Specifically, E-values of Cim A as glucuronidase (beta) inhibitors and lipoxigenase inhibitors are 2.23x10\textsuperscript{-18} and 8.65x10\textsuperscript{-4}, respectively (Table 1), suggesting significant similarity between Cim A and glucuronidase (beta) inhibitors as well as lipoxigenase inhibitors. Tc value of lipoxigenase inhibitors is 0.53—the highest Tc values of all protein inhibitors (Table 1), also suggesting Cim A as a lipoxigenase inhibitor. **TABLE 1**

**Prediction of Pharmacological Action of Cim A by SEA**

<table>
<thead>
<tr>
<th>Rank</th>
<th>Pharmacological action</th>
<th>E-value</th>
<th>Max Tc</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Glucuronidase (beta) Inhibitor</td>
<td>2.23x10\textsuperscript{-18}</td>
<td>0.37</td>
</tr>
<tr>
<td>2</td>
<td>Lipoxigenase Inhibitor</td>
<td>8.65x10\textsuperscript{-4}</td>
<td>0.53</td>
</tr>
<tr>
<td>3</td>
<td>Aldose Reductase Inhibitor</td>
<td>4.77x10\textsuperscript{-4}</td>
<td>0.38</td>
</tr>
<tr>
<td>4</td>
<td>Cylooxygenase Inhibitor</td>
<td>1.87x10\textsuperscript{-3}</td>
<td>0.50</td>
</tr>
<tr>
<td>5</td>
<td>HIV Integrase Inhibitor</td>
<td>9.45x10\textsuperscript{-3}</td>
<td>0.44</td>
</tr>
<tr>
<td>6</td>
<td>Adrenergic (beta1) Blocker</td>
<td>9.00x10\textsuperscript{-7}</td>
<td>0.40</td>
</tr>
<tr>
<td>7</td>
<td>Phospholipase A2 Inhibitor</td>
<td>1.27x10\textsuperscript{-1}</td>
<td>0.41</td>
</tr>
<tr>
<td>8</td>
<td>Tyrosine-Specific Protein Kinase Inhibitor</td>
<td>1.81</td>
<td>0.37</td>
</tr>
<tr>
<td>9</td>
<td>Dopamine Agonist</td>
<td>3.18</td>
<td>0.33</td>
</tr>
<tr>
<td>10</td>
<td>Phosphodiesterase Inhibitor</td>
<td>8.89</td>
<td>0.35</td>
</tr>
</tbody>
</table>

Example 2

**Determination of Inhibitory Effects of Cimicinamate A on 5-Lipoxygenase Activity**

[0125] This Example demonstrates that Cim A potently inhibits 5-LOX activity. Briefly, 5-LOX inhibition assay was performed by using Cayman’s lipoxigenase inhibitor screening assay kit (Cayman Chemical Company, Ann Arbor, Mich.) according to the manufacturer’s instructions. The 5-LOX and linoleic acid (substrate) were added simultaneously into dimethyl sulfoxide (DMSO)(Control) or Cim A at a concentration of 12.5, 25, and 50 μg/mL, respectively. After incubation for 5 min, developing reagents for the 5-LOX inhibition assay were added. Hydroperoxide production was measured using a microplate reader at a wavelength of 490 nm. The 5-LOX enzymatic activity is calculated as nmol/min/mL. The results showed that Cim A potently suppressed 5-LOX activity in a dose-dependent manner (FIG. 1A).

Example 3

**Determination of Inhibitory Effects of Cimicinamate A on LTβ Production**

[0126] This Example investigates the effects of Cim A on LTβ production. Briefly, freshly isolated human blood mononuclear cells (1x10\textsuperscript{5}) were pretreated with 0.05% DMSO or Cim A (25 or 50 μg/mL) for 1 hour, followed by the addition of calcium ionophore A23187 at a concentration of 5 (Sigma Aldrich, St. Louis, Mo.) for 30 min. After centrifugation for 1 min, the supernatant was collected. The level of leukotriene B4 (LTB4) was measured by using a LTB4 assay kit (R&D Systems, Minneapolis, Minn.). The results, as shown in FIG. 1B, demonstrate that Cim A inhibits the production of LTB4 in a dose-dependent manner.

Example 4

**Extraction of Cim A from Cimicifuga Species**

[0127] A light brown powder was obtained by repeated partitioning of the 80%EtOAc fraction prepared from the rhizomes of *Cimicifuga racemosa* and sequential chromatography on silica gel and reversed-phase HPLC. The detailed procedures are summarized in FIG. 2.

[0128] Using HPLC, the compound was eluted at approximate 9.4 min as a single compound with UV absorbance at wavelength 254, 210 and 280 nm (FIG. 3A). In FIG. 3B, the UV absorbance of the compound maximized at 290 and 325 nm, which revealed that it has a conjugated aromatic system. The compound showed a [M]+ ion peak at m/z 357.0952 in its HR-ESI-MS. Together with the 1H and 13C spectra data (FIG. 4), it was elucidated as Cim A (B22EES1-8-3).

Example 5

**Bio-Assays**

[0129] The chemical compound in *Cimicifuga racemosa* responsible for the inhibition of LPS-induced expression of TNF-α was identified. LPS is well known to be a potent inducer of TNF-α and its effects cannot be easily suppressed without the use of cytotoxic agents.

[0130] Bacterial endotoxin (lipopolysaccharide, LPS) stimulation of TNF-α induction in primary macrophages was used as a model of inflammatory diseases, since the production of TNF-α is an indicator of a key immune response.

[0131] Individual extracts isolated from *Cimicifuga racemosa* were incubated with PBMac for 24 hr prior to the addition of LPS for another 3 hr. Total RNA of the treated samples was isolated and subjected to RT-PCR assays using specific human TNF-α primers. The results showed that the fraction B22EES1 inhibits LPS-induced TNF-α mRNA expression (FIG. 5A, lanes 2 and 4). Among the sub-fractions of B22EES1, only B22EES1-4 and B22EES1-8 retained the suppressive activities for TNF-α induction (FIG. 5A, lanes 12 and 20).

Example 6

**Effects of Cim A on LPS-Induced Cytokine Production**

[0132] After the identification of B22EES1-8 as being responsible for the inhibitory effects on TNF-α, the activities of B22EES1-8 sub-fractions as described above were sepa-
rated and analyzed. A single molecule, namely Cin A
(H22EE1S1-8,3), was found to be the active compound
in the herbal extract responsible for the anti-inflammatory
effects.

[0133] To confirm the activities of Cin A in suppressing
TNF-α production, Cin A was incubated with PBMac for 24
hr prior to the addition of LPS at concentrations of 1 ng/mL
and 10 ng/mL for 24 hr. The culture supernatants were collected
and measured by ELISA for the level of secreted TNF-α.

[0134] Cin A inhibited the LPS-induced TNF-α protein
production by 47±10% and 58±30% at LPS concentrations of
1 ng/mL and 10 ng/mL, respectively (Fig. 6A, lanes 4 vs 5
and lanes 6 vs 7).

[0135] To further compare the efficiency of Cin A with
existing drugs, dexamethasone, a potent immunosuppressive
corticosteroid, was used as a prototype. PBMac were treated
with dexamethasone for 24 hr prior to the addition of LPS at
concentrations of 1 ng/mL and 10 ng/mL for 24 hr.

[0136] The results demonstrate that dexamethasone causes
a significant inhibition of LPS-induced TNF-α production by
32±7.5% and 25±6.3% at concentrations of 1.3 and 5.1 μM,
respectively (Fig. 6B).

Example 7

Molecular Mechanisms of Cytokine Downregulation
by Cin A

[0137] The molecular pathways involved in Cin A inhibition
of LPS-induced TNF-α production were elucidated. It is well
documented that the activation of cytokine production in
LPS-treated cells is initiated by the binding of LPS to its
receptor. After binding to the receptor, a cascade of signal-
ing kinases is activated. Among the activated kinases, MAP
kinases play a crucial role in LPS-induced cytokine produc-
tion. Previous studies illustrated that the induction of TNF-α
by LPS and other pathogens requires the phosphorylation
and activation of ERK1/2 and p38 MAPK.

[0138] In order to study the role of MAP kinases in Cin A
inhibition of TNF-α production, PBMac were treated with
Cin A for 24 hr and followed by the addition of LPS for 15
min. Protein samples were collected afterward and Western
blots were performed.

[0139] The results showed that LPS treatment results in
phosphorylation of two different MAP kinases, namely
ERK1/2 and p38 MAPK (Fig. 7, lane 2). With Cin A pre-
treatment, the phosphorylation of ERK1/2 (Fig. 7A, lanes 2
vs 4) but not p38 MAPK induced by LPS was suppressed
(Fig. 7B, lanes 2 vs 4).

[0140] These results demonstrated that the anti-inflammatory
activity of Cin A may be in part due to its inhibition of
ERK1/2 phosphorylation.

[0141] Along the signaling pathways regulated by MAP
kinases in response to LPS treatment, activation of the trans-
scription factor NF-κB plays a critical role in the induction
of proinflammatory cytokines including TNF-α. The activa-
tion of NF-κB involves degradation of its specific inhibitor
IKB and translocation of NF-κB sub-units from the cyto-
plasm to the nucleus. In accordance with the present inven-
tion, the addition of Cin A for 24 hr prior to the addition of LPS
reduced the translocation of NF-κB p65 subunit into the
nucleus.

[0142] The results showed that the addition of Cin A to
PBMac for 24 hr prior to the addition of LPS reduced the
amount of p65NF-κB in the nuclear fraction (Fig. 7C, lanes
2 vs 4), indicating that the translocation of the p65NF-κB to
the nucleus was inhibited by Cin A. In general, Cin A can
inhibit LPS-induced kinase activities and their consequent
activation of the nuclear transcription factor for TNF-α tran-
scription. Thus, the compounds of the present invention can
be used to regulate intracellular and/or extracellular activities
that are downstream from NF-κB and/or ERK1/2 in the cas-
cade of cellular events associated with inflammatory condi-
tions.

Example 8

Determination of the Presence of Cin A in
C. foetida and C. heraclefolia
Using HPLC-UV

[0143] Under the same HPLC conditions, the retention
time and the UV absorbance of Cin A were compared with
the characteristic peak in the chromatograms of CF22EE1S1
and CH22EE1S1. In Figs. 8A and B, both samples had a
peak with retention time at approximate 9.4 min and their
respective UV absorbance was same as that of Cin A (Figs.
3A & B). The results revealed that herbs including C. foetida
and C. heraclefolia contained Cin A.

Example 9

Determination of the Presence of Cin A in
C. foetida and C. heraclefolia
Using UPLC-TOF-MS

[0144] Under the same UPLC and ESI-MS conditions, the
retention time and the mass-to-charge ratio of B8-3 (Cin A)
were compared to the characteristic peak in the chromato-
grams and spectra of CF22EE1S1 and CH22EE1S1. In Figs.
9A and B, both samples had a peak with retention time at
approximate 6 min with an ion peak at m/z 357 that was the
same as that of Cin A (Fig. 9A). The results revealed that
herbs including C. foetida and C. heraclefolia contained
B8-3 (Cin A).

REFERENCES


[0146] 2. Samuelsson, B., “Leukotrienes: Mediators of
Immediate Hypersensitivity Reactions and Inflammation,”

[0147] 3. Weissmann, G., “Prostaglandins as Modulators
Rather than Mediators of Inflammation,” J. Lipid Mediators,

[0148] 4. Jampilek, J.; Dolezel, M.; Opletalova, V.; Hurlt,
J., “5-Lipoxygenase, Leukotriene Biosynthesis and

[0149] 5. Ding, X.-Z.; Hennig, R.; Adrian, T. E., “Lipoxygen-
ase and cyclooxygenase metabolism: new insights in
treatment and chemoprevention of pancreatic cancer,”

[0150] 6. Pommeren, N.; Taverne, T.; Telliez, A.; Goossens,
L.; Charlier, C.; Pommeren, J.; Goossens, J.-F.; Houssein, R.;
Durant, F.; He‘nichard, J.-P., “New COX-2/S-LOX Inhibi-
tors: Apoptosis-Inducing Agents Potentially Useful in
Prostate Cancer Chemotherapy,” J. Med. Chem., Oct. 30,


[0178] 34. Matsuyama et al., The target of 5-lipoxigenase is a novel strategy over human urolologic tumors than the target of cyclooxygenase-2, Drug Target Insights 2008: 3 137-151.


<160> NUMBER OF SEQ ID NOS: 4

<210> SEQ ID NO 1
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer set for TNF-alpha (upstream)

<400> SEQUENCE: 1
ggctcagcgc gggtgcttgct c

<210> SEQ ID NO 2
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer set for TNF-alpha (downstream)

<400> SEQUENCE: 2
agagggctag ggctgctag

<210> SEQ ID NO 3
We claim:

1. A method for reducing 5-lipoxygenase (5-LOX) activity, wherein said method comprises administering, to a subject in need of such treatment, an effective amount of an isolated compound or a product thereof, wherein the compound has the following formula:

![Chemical structure diagram]

wherein

- $R_1$ is alkyl;
- $R_2$ is $H$ or alkyl;
- $R_3$, $R_4$, and $R_7$ are independently $-H$, acyl, halo, haloalkyl, amino, alkylamino, hydroxyl, alkyl, hydroxyalkyl, or $-COOH$;
- $R_8$ is $-O$ or $-NH$;
- $R_9$ is $-H$, alkyl, alkoxy, hydroxyalkyl, hydroxyl, or halo;
- $R_{10}$, $R_{11}$, and $R_{12}$ are independently $-H$, acyl, halo, aminoalkylamino, hydroxyl, alkyl, hydroxyalkyl, or $-COOH$;
- $R_{13}$ is $H$ or alkyl; and
- $R_{14}$ is $H$ or alkyl;

wherein the method is used to treat a disease or condition selected from the group consisting of inflammation, allergy or allergic reaction, cardiovascular disease, cerebrovascular disease, neangiogenesis, respiratory or pulmonary disorder, skin disorder, asthma or asthma-related condition, arthritis, and cancer or tumor.

2. The method, according to claim 1, wherein the subject is a human.

3. The method, according to claim 1, wherein $R_2$ is $H$, $R_3$ is $H$, and $R_4$ is $H$.

4. The method, according to claim 3, wherein $R_1$ is a methyl group.

5. The method, according to claim 4, wherein the isolated compound is:

![Compound structure diagram]

6. The method, according to claim 1, wherein the compound is isolated from a *Cimicifuga* species.

7. The compound, according to claim 6, wherein the compound is isolated from a *Cimicifuga* selected from the group consisting of *Cimicifuga racemosa*, *Cimicifuga foetida*, and *Cimicifuga heraclefolia*.

8. The method, according to claim 1, used to reduce biosynthesis of $LTA_2$, $LTB_4$, $LTE_2$, and/or $LTE_4$.

9. The method, according to claim 8, used to reduce biosynthesis of $LTD_4$.

10. The method, according to claim 1, used to reduce cAMP or CGMP level.

11. The method, according to claim 1, used to reduce activity of aldose reductase, cyclooxygenase, HIV integrase, adrenergic (beta1), and/or phospholipase A2.

12. The method, according to claim 1, used to reduce biosynthesis of prostaglandins or thromboxane.

13. The method, according to claim 1, wherein the method is used to treat a disease selected from asthma, rhinitis, chronic obstructive pulmonary disease, cerebrovascular disease, or myocardial infarction.

14. The method, according to claim 1, wherein the method is used to treat bronchial asthma.

15. The method, according to claim 1, wherein the method is used to treat allergic rhinitis.

16. The method, according to claim 1, wherein the method is used to treat a cerebrovascular and/or cardiovascular disease selected from the group consisting of myocardial infarction, acute myocardial infarction, stroke, atherosclerosis, thrombosis, coronary angioplasty, angina, myocardial ischemia, hypertension, platelet aggregation, aortic aneu-
ysts, vascular inflammation, intimal hyperplasia, or hyperlipidemia-dependent aortic aneurysm.
17. The method, according to claim 1, wherein the method is used to treat a respiratory or pulmonary condition selected from the group consisting of cystic fibrosis lung diseases, sleep-disorder breathing, obstructive sleep apnea (OSA), and chronic obstructive pulmonary disease (COPD).
18. The method, according to claim 1, wherein the method is used to treat tumor or cancer.
19. The method, according to claim 18, wherein the cancer or tumor is selected from the group consisting of urological tumor, renal cell carcinoma, bladder tumor, prostate cancer, and pancreatic cancer.
20. The method, according to claim 1, used to inhibit neangiogenesis.